Progyny, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; the filing also provides unaudited fourth-quarter results. Filed February 29, 2024. Progyny manages employer-sponsored fertility and family-building benefits, including its Smart Cycle treatment benefit and optional Progyny Rx pharmacy benefit.
Financial and operating performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $1,088.6 million | $786.9 million | +38% |
| Gross profit / margin | $238.8 million / 21.9% | $167.3 million / 21.3% | +43% / +0.6 percentage points |
| Operating income / margin | $62.2 million / 5.7% | $23.3 million / 3.0% | +166% |
| Net income | $62.0 million | $30.4 million | +104% |
| Diluted EPS | $0.62 | $0.30 | Up |
| Adjusted EBITDA (non-GAAP) | $187.1 million | $125.7 million | +49% |
| Cash provided by operating activities | $188.8 million | $80.4 million | +135% |
- Revenue growth reflected fertility-benefit revenue of $676.3 million (+33%) and pharmacy-benefit revenue of $412.3 million (+49%). Management attributed growth primarily to more clients and covered lives, including increased Progyny Rx adoption.
- Cost of services rose 37%, slightly below revenue growth. Gross margin improved mainly from care-management efficiencies, partly offset by planned cost-containment efforts shared with clients.
- Sales and marketing expense increased 30%; general and administrative expense increased 19%, including higher personnel and stock-based compensation costs. Stock-based compensation totaled $122.6 million, versus $100.7 million in 2022.
- The 2023 tax provision was $8.7 million, compared with a $5.9 million tax benefit in 2022. The filing attributes the change primarily to higher operating profit and lower equity-compensation tax benefits.
- At December 31, cash and cash equivalents were $97.3 million and marketable securities were $273.8 million. Current assets were $640.4 million versus current liabilities of $186.0 million. The filing reports no outstanding debt; the former SVB revolving credit line matured in 2021. Lease liabilities totaled $19.4 million.
- Operating cash flow benefited from earnings, noncash stock compensation and pharmacy-partner payment timing, including a $20.0 million prepayment. Accounts receivable increased $21.7 million and prepaid/current assets increased $22.9 million during the year. Investing cash outflow was $200.5 million, largely from net purchases of marketable securities.
Fourth-quarter results and year-over-year comparison
Q4 2023 revenue was $269.9 million, up about 26% from $214.3 million in Q4 2022. Gross profit was $56.9 million versus $44.5 million; operating income was $13.8 million versus $3.3 million; and net income was $13.5 million versus $3.4 million. Diluted EPS was $0.13 versus $0.03. The filing’s quarterly table shows Q4 revenue below Q3 2023 revenue of $280.9 million, with net income also lower sequentially.
Business developments, outlook and risks
- At year-end, Progyny reported 392 active clients and 5.418 million members in its operating metrics, compared with 288 clients and 4.585 million members a year earlier. Separately, it described more than 450 employer contracts and approximately 6.4 million covered lives under contract. Progyny Rx was used by 91% of clients.
- Annual ART cycles increased to 58,013 from 42,598. Annual utilization among all members rose to 1.33% from 1.23%. Management cited strong client retention, expanding adoption and a large addressable market; it also described moderate seasonality, with a larger share of revenue generally in the second half.
- The filing refers to first-quarter and full-year 2024 guidance issued February 27, 2024, but the guidance values are not provided in the supplied filing text. Management states that cash and cash equivalents, marketable securities and operating cash flow should fund working capital and capital needs for at least the next 12 months.
- In February 2024, the board authorized repurchases of up to $100 million of common stock; the filing gives no assurance that any shares will be repurchased.
- Key risks include client concentration (one client represented 13% of 2023 revenue), exposure to technology-industry clients, competition, changes in treatment utilization, provider-network and specialty-drug supply disruptions, and evolving healthcare, pharmacy-benefit, privacy and reproductive-rights regulation. Cybersecurity incidents or service disruptions at Progyny or third parties could also affect operations.
- Management reported no cybersecurity threat in 2023 that materially affected or was reasonably likely to materially affect the company. The company disclosed no litigation it believed would have a material adverse effect. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Important facts for investors to verify
- Review the February 27, 2024 guidance and subsequent results; guidance figures are not included in the supplied text.
- Assess whether client/member growth and Progyny Rx adoption continue, and monitor the largest client’s renewal and revenue contribution.
- Evaluate cash-flow quality, including pharmacy-partner timing and prepayments, receivable allowances, and the large noncash stock-based compensation expense.
- Track gross-margin trends alongside treatment utilization, provider and medication costs, and any changes to client pricing or cost-containment arrangements.
- Review the $100 million repurchase authorization, lease commitments, potential dilution from outstanding equity awards, and regulatory or reproductive-rights developments.